CN102171205B - 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂 - Google Patents

促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂 Download PDF

Info

Publication number
CN102171205B
CN102171205B CN2009801386016A CN200980138601A CN102171205B CN 102171205 B CN102171205 B CN 102171205B CN 2009801386016 A CN2009801386016 A CN 2009801386016A CN 200980138601 A CN200980138601 A CN 200980138601A CN 102171205 B CN102171205 B CN 102171205B
Authority
CN
China
Prior art keywords
crf
cyclopropyl
mmol
reaction mixture
methoxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801386016A
Other languages
English (en)
Chinese (zh)
Other versions
CN102171205A (zh
Inventor
理查德·A·哈茨
维杰伊·T·阿赫加
维夫卡南达·M·弗鲁德赫拉
乔安妮·J·布朗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102171205A publication Critical patent/CN102171205A/zh
Application granted granted Critical
Publication of CN102171205B publication Critical patent/CN102171205B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801386016A 2008-07-31 2009-04-27 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂 Expired - Fee Related CN102171205B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8523008P 2008-07-31 2008-07-31
US61/085,230 2008-07-31
PCT/US2009/041793 WO2010014280A1 (en) 2008-07-31 2009-04-27 Pyrazinone modulator of corticotropin-releasing factor receptor activity

Publications (2)

Publication Number Publication Date
CN102171205A CN102171205A (zh) 2011-08-31
CN102171205B true CN102171205B (zh) 2013-08-07

Family

ID=40651774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801386016A Expired - Fee Related CN102171205B (zh) 2008-07-31 2009-04-27 促肾上腺皮质激素释放因子受体活性的吡嗪酮调节剂

Country Status (10)

Country Link
US (2) US7932256B2 (cg-RX-API-DMAC7.html)
EP (1) EP2303867B1 (cg-RX-API-DMAC7.html)
JP (1) JP5396474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110040870A (cg-RX-API-DMAC7.html)
CN (1) CN102171205B (cg-RX-API-DMAC7.html)
AR (1) AR072639A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009277057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011000754A (cg-RX-API-DMAC7.html)
TW (1) TW201008926A (cg-RX-API-DMAC7.html)
WO (1) WO2010014280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
IT201900021216A1 (it) 2019-11-14 2021-05-14 Isagro Spa Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
CN112552184B (zh) * 2020-12-18 2022-05-10 诚达药业股份有限公司 一种含环丙基手性胺盐酸盐的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
HRP20031096A2 (en) * 2001-06-12 2005-08-31 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Also Published As

Publication number Publication date
TW201008926A (en) 2010-03-01
WO2010014280A1 (en) 2010-02-04
EP2303867B1 (en) 2014-12-17
MX2011000754A (es) 2011-02-24
US8372847B2 (en) 2013-02-12
JP2011529886A (ja) 2011-12-15
US20110166160A1 (en) 2011-07-07
AR072639A1 (es) 2010-09-08
US7932256B2 (en) 2011-04-26
JP5396474B2 (ja) 2014-01-22
AU2009277057A1 (en) 2010-02-04
CN102171205A (zh) 2011-08-31
US20100029684A1 (en) 2010-02-04
KR20110040870A (ko) 2011-04-20
EP2303867A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
US8372847B2 (en) Pyrazinone modulator of corticotropin-releasing factor receptor activity
JP5439169B2 (ja) 三置換1,2,4−トリアゾール
KR102531689B1 (ko) 6,7―디히드로피라졸로[1,5―α]피라진―4(5H)―온 화합물 및 MGLUR2 수용체의 음성 알로스테릭 조절제로서의 그 용도
JP4187652B2 (ja) ニューロペプチドyアンタゴニストとしてのキノリン誘導体
MX2008010668A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
CN110997652B (zh) 哌啶酮甲酰基肽2受体激动剂
EP3174884B1 (en) 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
AU2015357167B2 (en) 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JP2009527562A (ja) ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体
EP3174882B1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
TW201625581A (zh) 側氧雜環衍生物
AU2015295299B2 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JP7785291B2 (ja) TrkBポジティブアロステリックモジュレーター
CN1443763A (zh) 制备喹喔啉二酮的中间体
TW201609718A (zh) 唑啶以及噁嗪烷衍生物
CN1930131A (zh) 2H-或3H-苯并[e]吲唑-1-基的氨基甲酸酯衍生物、其制备及其在治疗上的应用
CZ9903052A3 (cs) Chinoxalindiony, způsoby a meziprodukty pro jejich výrobu, jejich použití, farmaceutické přípravky na jejich bázi a způsoby léčení

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130807

Termination date: 20140427